{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:14:07Z","timestamp":1778832847839,"version":"3.51.4"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["UL1 TR000448"],"award-info":[{"award-number":["UL1 TR000448"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R03 AG042374"],"award-info":[{"award-number":["R03 AG042374"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jgo.2020.05.004","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T01:17:18Z","timestamp":1590542238000},"page":"1279-1284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment"],"prefix":"10.1016","volume":"11","author":[{"given":"Hira","family":"Mian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory R.","family":"Pond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha A.","family":"Tuchman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Fiala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2020.05.004_bb0005","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","first-page":"2008","article-title":"Lyon, France: IARC Press","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.jgo.2020.05.004_bb0010","series-title":"SEER Cancer statistics review, 1975\u20132007","year":"2010"},{"issue":"1","key":"10.1016\/j.jgo.2020.05.004_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","article-title":"The frailty syndrome: definition and natural history","volume":"27","author":"Xue","year":"2011","journal-title":"Clin Geriatr Med"},{"issue":"3","key":"10.1016\/j.jgo.2020.05.004_bb0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jgo.2018.05.015","article-title":"Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant","volume":"10","author":"Rosko","year":"2019","journal-title":"J Geriatr Oncol"},{"issue":"13","key":"10.1016\/j.jgo.2020.05.004_bb0025","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2020.05.004_bb0030","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.jgo.2020.05.004_bb0035","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.24532","article-title":"N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma","volume":"91","author":"Milani","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jgo.2020.05.004_bb0040","article-title":"Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma","volume":"2","author":"Mian","year":"2018","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"10.1016\/j.jgo.2020.05.004_bb0045","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/hematology.2019000076","article-title":"Evidence-Based Minireview: Longitudinal geriatric assessment in quality care for older patients with hematologic malignancies","volume":"2019","author":"Lin","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"15_suppl","key":"10.1016\/j.jgo.2020.05.004_bb0050","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1200\/JCO.2018.36.15_suppl.10009","article-title":"Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT)","volume":"36","author":"Celis","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jgo.2020.05.004_bb0055","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/jgs.15715","article-title":"Geriatric Assessment in Older Adults with Multiple Myeloma","volume":"67","author":"Wildes","year":"2019","journal-title":"J Am Geriatr Soc."},{"issue":"15","key":"10.1016\/j.jgo.2020.05.004_bb0060","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol."},{"issue":"25","key":"10.1016\/j.jgo.2020.05.004_bb0065","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","article-title":"Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.05.004_bb0070","series-title":"Measuring functioning and well-being: The medical outcome study approach (pp. 345\u2013371). Durham","article-title":"Summary and discussion of MOS measures","author":"Steward","year":"1992"},{"issue":"4","key":"10.1016\/j.jgo.2020.05.004_bb0075","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/089198879500800408","article-title":"Reliability of the Blessed Telephone Information-Memory-Concentration Test","volume":"8","author":"Kawas","year":"1995","journal-title":"J Geriatr Psychiatry Neurol."},{"issue":"2","key":"10.1016\/j.jgo.2020.05.004_bb0080","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \"Up & Go\": a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc."},{"issue":"3","key":"10.1016\/j.jgo.2020.05.004_bb0085","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1227\/NEU.0000000000001320","article-title":"Assessment of the Minimum Clinically Important Difference in the Timed Up and Go Test After Surgery for Lumbar Degenerative Disc Disease","volume":"80","author":"Gautschi","year":"2017","journal-title":"Neurosurgery."},{"issue":"3","key":"10.1016\/j.jgo.2020.05.004_bb0090","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1016\/j.jgo.2020.05.004_bb0095","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/ijgc-00009577-200311000-00003","article-title":"Psychometric evaluation of the Functional Assessment of Cancer Therapy\/Gynecologic Oncology Group-Neurotoxicity (Fact\/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy","volume":"13","author":"Calhoun","year":"2003","journal-title":"Int J Gynecol Cancer."},{"issue":"3","key":"10.1016\/j.jgo.2020.05.004_bb0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-019-0181-0","article-title":"Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma","volume":"9","author":"Ludwig","year":"2019","journal-title":"Blood Cancer J"},{"issue":"19","key":"10.1016\/j.jgo.2020.05.004_bb0105","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2005.04.7779","article-title":"Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib","volume":"24","author":"Richardson","year":"2006","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1016\/j.jgo.2020.05.004_bb0110","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The functional assessment of Cancer therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2020.05.004_bb0115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","article-title":"Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella","year":"2002","journal-title":"J Pain Symptom Manag"},{"issue":"13","key":"10.1016\/j.jgo.2020.05.004_bb0120","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.jgo.2020.05.004_bb0125","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/asheducation-2018.1.88","article-title":"Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist","volume":"2018","author":"Wildes","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jgo.2020.05.004_bb0130","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1200\/EDBK_239067","article-title":"Approach to the older adult with multiple myeloma","volume":"39","author":"Mina","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.jgo.2020.05.004_bb0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia."},{"issue":"Supplement_1","key":"10.1016\/j.jgo.2020.05.004_bb0140","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2019-126207","article-title":"Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV","volume":"134","author":"Cairns","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jgo.2020.05.004_bb0145","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14301","article-title":"Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia","volume":"64","author":"Klepin","year":"2016","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.jgo.2020.05.004_bb0150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jgo.2015.04.002","article-title":"Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age","volume":"6","author":"Alibhai","year":"2015","journal-title":"J Geriatr Oncol."},{"issue":"4","key":"10.1016\/j.jgo.2020.05.004_bb0155","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"The Lancet Oncology"},{"issue":"3","key":"10.1016\/j.jgo.2020.05.004_bb0160","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2018.01.005","article-title":"Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies","volume":"18","author":"Fakhri","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement_1","key":"10.1016\/j.jgo.2020.05.004_bb0165","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood-2019-121672","article-title":"Undertreatment of Older Patients with Newly-Diagnosed Multiple Myeloma: Real World Evidence from a Canadian Registry Cohort","volume":"134","author":"Mian","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jgo.2020.05.004_bb0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ctrv.2014.12.010","article-title":"A systematic review of factors influencing older adults' decision to accept or decline cancer treatment","volume":"41","author":"Puts","year":"2015","journal-title":"Cancer Treat Rev."},{"issue":"4","key":"10.1016\/j.jgo.2020.05.004_bb0175","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood.2019000758","article-title":"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2020.05.004_bb0180","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1532-5415.2011.03336.x","article-title":"Is timed up and go better than gait speed in predicting health, function, and falls in older adults?","volume":"59","author":"Viccaro","year":"2011","journal-title":"Journal of the American Geriatrics Society."},{"key":"10.1016\/j.jgo.2020.05.004_bb0185","article-title":"Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed\/refractory multiple myeloma, based on German benefit assessment data","author":"Weisel","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jgo.2020.05.004_bb0190","article-title":"Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study","author":"Nielsen","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2020.05.004_bb0195","article-title":"Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial","author":"Schjesvold","year":"2019","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1016\/j.jgo.2020.05.004_bb0200","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.jgo.2020.05.004_bb0205","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29119","article-title":"Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage","volume":"121","author":"Kent","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2020.05.004_bb0210","article-title":"Unmet needs and quality of life in multiple myeloma patients","volume":"1359105318772073","author":"Pereira","year":"2018","journal-title":"J Health Psychol"},{"key":"10.1016\/j.jgo.2020.05.004_bb0215","article-title":"Physical activity and health-related quality of life in multiple myeloma survivors: the PROFILES registry","author":"Servadio","year":"2019","journal-title":"BMJ Support Palliat Care"},{"issue":"4","key":"10.1016\/j.jgo.2020.05.004_bb0220","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00277-014-2264-0","article-title":"Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry","volume":"94","author":"van der Poel","year":"2015","journal-title":"Ann Hematol."},{"issue":"8","key":"10.1016\/j.jgo.2020.05.004_bb0225","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.bbmt.2018.03.027","article-title":"Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma","volume":"24","author":"Chakraborty","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jgo.2020.05.004_bb0230","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.13316","article-title":"Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients","volume":"103","author":"Sully","year":"2019","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.jgo.2020.05.004_bb0235","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3109\/10428194.2013.847933","article-title":"Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >\/= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial","volume":"55","author":"Dimopoulos","year":"2014","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820301004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820301004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:01:41Z","timestamp":1778832101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406820301004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1879406820301004"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2020.05.004","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2020.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}